Live Feeds
● TRACKER Updated 21d ago · 8 sources tracked

U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute

A US court has ordered Guardant Health to pay $245 million in a DNA sequencing patent dispute with TwinStrand Biosciences and the University of Washington. The dispute centred on patent infringement claims. Guardant plans to appeal the ruling.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Guardant Health was ordered to pay $245 million in a DNA sequencing patent dispute.
  • ✓ The patent dispute involved TwinStrand Biosciences and the University of Washington.
  • ✓ Guardant plans to appeal the court's ruling.
🛡️ Source Corroboration: 8 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

A US court has ordered Guardant Health to pay $245 million in damages, with Guardant planning to appeal the ruling.

Live updates

  1. Guardant ordered to pay $245 million in DNA sequencing patent dispute

    A US court has ordered Guardant Health to pay $245 million in a DNA sequencing patent dispute with TwinStrand Biosciences and the University of Washington. The dispute centred on patent infringement claims. Guardant plans to appeal the ruling.

    Why it matters

    This ruling marks a significant development in the ongoing patent dispute between Guardant Health and TwinStrand Biosciences, a company focused on advancing cancer research through innovative genomic solutions. The case highlights the competitive and litigious nature of the genetic testing and sequencing industry. Guardant Health is a leading player in the field of liquid biopsy and genomic testing for cancer.

    What is confirmed

    • Guardant Health was ordered to pay $245 million in a DNA sequencing patent dispute.
    • The patent dispute involved TwinStrand Biosciences and the University of Washington.
    • Guardant plans to appeal the court's ruling.

    What to watch next

    • Guardant Health's appeal of the court's ruling
    • any potential impact on Guardant Health's stock price
    • further developments in the patent dispute
    Sources used for this update (8)
    1. Reuters — U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute
    2. Endpoints News — TwinStrand wins patent case; GSK’s hepatitis B drug approved in Japan
    3. Investor's Business Daily — Guardant Bleeds After Losing A Costly Patent Dispute
    4. Seeking Alpha — Guardant Health loses patent judgment; ordered to pay $245M
    5. GuruFocus — Guardant Health Inc (GH) Shares Fall 4.4% -- What GF Score of 65 Tells Investors
    6. The Business Journals — TwinStrand, UW awarded $245 million in patent infringement suit
    7. www.devdiscourse.com — Reuters Health News Summary
    8. finance.yahoo.com — Guardant ordered to pay $245m in DNA sequencing patent dispute
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community